Epstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature Review

Kiyomi Mashima¹, Shingo Yano¹, Hiroki Yokoyama¹, Takeshi Saito¹, Tomohito Machishima¹, Takaki Shimada¹, Yuichi Yahagi¹, Shinobu Takahara¹, Katsuki Sugiyama¹, Yoji Ogasawara¹, Jiro Minami¹, Yutaro Kamiyama¹, Atsushi Katsube¹, Kazuhiro Suzuki¹, Sayaka Ohshima¹, Hisashi Yamada², Noriko Usui³ and Keisuke Aiba¹

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs) sometimes occur following Anti-thymocyte globulin (ATG) administration for allogenic stem cell transplantation but are rare in aplastic anemia (AA) patients. A 55-year-old woman with AA following ATG developed refractory fever and was diagnosed with EBV-LPD. She was successfully treated with weekly rituximab monotherapy; however, she developed EBV encephalitis. She was admitted to the intensive care unit and finally recovered from unconsciousness. EBV-LPD should be considered after ATG for AA when symptoms appear. Because EBV-LPD following ATG for AA can rapidly progress, weekly monitoring of EBV-DNA and early intervention may be necessary.

Key words: Anti-thymocyte globulin, Epstein-Barr virus, aplastic anemia, encephalitis, rituximab, lymphoproliferative disorder

(Intern Med 56: 701-706, 2017)  
(DOI: 10.2169/internalmedicine.56.7722)

Introduction

Epstein-Barr virus (EBV) is a gammaherpesvirus that latently infects approximately 90% of human adults. The main targets of EBV infection are naïve B-cells, which are activated to proliferating blasts. Infection by EBV and the spread of EBV are controlled by host antibodies and cytotoxic T lymphocytes (CTLs). However, the host immune system cannot completely eliminate EBV; therefore, infected B cells can persist at low levels (1).

Anti-thymocyte globulin (ATG) is a rabbit-derived polyclonal antibody with a high affinity for T cells and leukocyte surface antigens. ATG reduces the levels of antigen-reactive T cells in the peripheral blood. Impairment of the CTL response is associated with abnormal proliferation of B cells. Post-transplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmatic proliferation disorders that develop after solid organ transplantation or allogeneic hematopoietic stem cell transplantation (allo-HSCT) because of immunosuppression (2). ATG-containing conditioning regimens have been reported to increase the risk of PTLDs (3-5). The recommended strategy for the prevention of PTLDs is the reduction of immunosuppression with or without preemptive rituximab therapy, based on regular monitoring of EBV deoxyribonucleic acid (EBV-DNA) loads in peripheral blood. Preemptive rituximab therapy has been reported to prevent the development of PTLDs in ap-

¹Department of Oncology and Hematology, The Jikei University School of Medicine, Japan, ²Research Center for Medical Science, Core Research Facilities for Basic Science (Molecular Genetics), The Jikei University School of Medicine, Japan and ³Department of Oncology and Hematology, The Jikei University School of Medicine, Daisan Hospital, Japan

Received for publication May 18, 2016; Accepted for publication July 3, 2016
Correspondence to Dr. Keisuke Aiba, aiba@jikei.ac.jp
EBV-LPD and EBV encephalitis following ATG therapy

Case Report

The initial treatment of newly diagnosed acquired severe aplastic anemia is allogeneic bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-identical sibling donor, if available, for patients <40 year of age (7, 8). Immunosuppressive therapy is recommended for patients ≥40 years of age or with no HLA-identical sibling donor (9). In the setting of allo-HSCT, ATG is associated with an increased risk of EBV reactivation and PTLD (10). Scheinberg et al. reported that EBV reactivation occurred in 100% of EBV-seropositive patients after receiving rabbit ATG at a dose of 3.5 mg/kg with cyclosporin A (CsA) therapy for severe aplastic anemia (11).

The risk factors for EBV-LPD following treatment for aplastic anemia have not yet been determined. With regard to PTLD following allo-SCT, the risk factors include a T cell depletion treatment regimen, patient age >50 years, second allo-HCT, the presence of graft-versus-host disease, the use of cord blood, and haploidentical transplant (6). In patients with aplastic anemia, the reactivation of EBV following treatment using rabbit ATG was reported more severe than that following treatment using horse ATG or alemtuzumab (11, 12).

Ten cases of EBV reactivation and/or LPDs following immunosuppressive therapy for aplastic anemia have been reported in the literature. However, to our knowledge, the outcome of EBV encephalitis following ATG therapy has not been reported (13-22). EBV-associated lymphoproliferative disorders (EBV-LPDs) following ATG therapy for aplastic anemia are rapidly progressive and often fatal. Reduction of immunosuppression and rituximab monotherapy with or without combination chemotherapy have been reported as treatment options for EBV-LPDs and PTLDs. We herein report a case of a patient with aplastic anemia who developed EBV-LPD and EBV encephalitis following ATG therapy who was successfully treated using rituximab monotherapy.

A 55-year-old woman was referred to our hospital because of pancytopenia. Her medical history included lumpectomy and adjuvant radiochemotherapy for breast cancer at 49 years of age. Because her peripheral blood count had gradually decreased, she was admitted to our department in May 2012. On a physical examination, the patient had conjunctival pallor and local purpura of her lower legs. Laboratory studies revealed pancytopenia with an absolute neutrophil count of 0.4×10^9/L, reticulocyte count of 47.8×10^9/L, and platelet count of 17×10^9/L. Bone marrow aspiration and biopsy showed severely hypoplastic marrow with 90% of the normal tissue replaced by adipose tissue with no blasts or mature cells. There were no atypical or malignant cells present. Magnification×100. Hematoxylin and Eosin staining.

Figure 1. Photomicrograph of the patient’s bone marrow smear at the time of diagnosis of aplastic anemia. Ninety percent of the normal bone marrow tissue was replaced by adipose tissue with no blasts or mature cells. There were no atypical or malignant cells present. Magnification×100. Hematoxylin and Eosin staining.

Intern Med 56: 701-706, 2017 DOI: 10.2169/internalmedicine.56.7722
Forty-five days after ATG initiation, the serum LDH level was elevated to more than 3,000 U/L, and the serum EBV-DNA level increased to $1.1 \times 10^6$ copies/10⁶ cells. Following rituximab therapy, these levels rapidly decreased. Rituximab was administered once a week for 8 weeks.

Although her general status and laboratory data had improved, she suddenly fell unconscious three days after the second cycle of rituximab. Cranial T2-weighted MRI and fluid-attenuated inversion recovery (Fig. 5) showed high-intensity lesions in her cerebral cortex. A polymerase chain reaction (PCR) analysis for herpes simplex virus 1, 2 (HSV-1, 2), EBV, human herpes virus 6 (HHV-6), varicella zoster virus (VZV), and cytomegalovirus (CMV) was performed using the cerebrospinal fluid (CSF), and EBV-DNA was detected in the CSF sample. After EBV encephalitis with LPD was diagnosed, we administered ganciclovir and intravenous immunoglobulin (IVIG). As shown in Fig. 2, a real-time PCR analysis showed that the serum EBV-DNA level had rapidly decreased, and she regained consciousness. After eight subsequent courses of rituximab treatment, the EBV-DNA loads decreased below the detection limit, and the symptoms of EBV-LPDs and EBV encephalitis disappeared.

A CT scan also revealed that there was no evidence of hepato-
tosplenomegaly, enlarged gallbladder, or abdominal lymphadenopathy (Fig. 6). Twenty-two months following ATG initiation, she achieved a partial response for aplastic anemia according to the response criteria previously described by Camitta (8). To date, EBV-LPD recurrence has not been observed.

**Discussion**

This case report demonstrated that EBV-associated LPD with EBV encephalitis following ATG therapy for aplastic anemia can be successfully treated with rituximab. This finding may have implications for future patient treatment because it suggests that early detection of EBV-DNA and EBV reactivation may be beneficial for patients receiving ATG treatment for aplastic anemia.

Ten previously reported cases of EBV reactivation and/or LPD following immunosuppressive therapy for aplastic anemia from the literature can be compared with this case, although no case included EBV encephalitis (13-22). As shown in Table, six previously reported patients with LPD achieved a complete response (CR) with reduction of immunosuppression and/or combination chemotherapy (14, 16-19, 22). The initial signs of EBV-LPDs are a fever, general fatigue, loss of appetite, lymphadenopathy, hepatosplenomegaly, appearance of atypical lymphocytes in peripheral blood, and/or elevation of serum LDH (13-22). In our case, the cessation of immunosuppressive agents did not improve the symptoms of EBV-LPD; however, rituximab monotherapy resulted in a CR.

Weekly monitoring of the peripheral EBV-DNA load is recommended for high-risk patients following allo-HSCT (23). The peak incidence of early PTLDs occurs 6-12 months following allo-HSCT (24). EBV-LPDs in patients with aplastic anemia may occur earlier than in patients with PTLDs. Therefore, it may be reasonable to begin monitoring within a week after ATG initiation.

With regard to allo-HSCT, patients with EBV reactivation and sufficient T cells improved only by reduction of immunosuppression (25). Among patients who developed PTLDs following allo-HSCT, the response rate for rituximab with the reduction of immunosuppression was 84%, whereas the rate was only 61% without a reduction of immunosuppression (26). Our patient did not improve following reduction of immunosuppression; therefore, an anticancer agent was administered. This indicates that the reduction of immunosuppression following the development of LPDs may be less effective for EBV-LPDs after ATG than for PTLDs, which may be partly because EBV-LPDs following ATG for aplastic anemia generally develop before T cell reconstitution.

Other EBV-associated diseases sometimes concurrently develop with PTLDs. Three major EBV end-organ diseases in recipients of allo-HSCT are pneumonitis, encephalitis/myelitis, and hepatitis (27). Reportedly, EBV-associated diseases are more refractory to rituximab than other agents (27). The MRI features of central nervous system (CNS)-involved PTLD that develop after solid-organ transplantation are multiple contrast-enhancing, intra-axial lesions associated with extensive peritumoral edema (28). CNS-involved PTLD masses are generally hypercellular, appearing hypo- to isointense on both plain T1- and T2-weighted MRI (29). Unlike CNS-involved PTLD, EBV encephalitis is reported to appear hyperintense on plain T2-weighted and fluid-attenuated inversion recovery (FLAIR) MRI (30). Because EBV-DNA was detected in the CSF and cranial MRI T2-weighted and FLAIR revealed a high-intensity cerebral cortex without masses or peritumoral edema, we suspected
our patient of having EBV encephalitis and not EBV-LPD with CNS involvement.

In conclusion, we reported a case of EBV-LPD with EBV encephalitis following ATG therapy in a patient with aplastic anemia who was successfully treated using rituximab. This case demonstrates that, in patients with aplastic anemia who are treated using ATG therapy, the initial symptoms of EBV-LPD should be considered. Because EBV-LPD following treatment for aplastic anemia progresses more rapidly than PTLD, weekly monitoring of EBV-DNA may be necessary. If EBV-LPD develops during treatment for aplastic anemia, a reduction in immunosuppressive treatment may be insufficient; therefore, preemptive treatment using rituximab should be considered.

The authors state that they have no Conflict of Interest (COI).

Consent for publication
Informed consent was obtained form the patient for publication.

Acknowledgement
We thank Ms. Yumiko Inui (Kobe University) for the useful advice regarding our medical practice.

Author contributions
KM, SY, and HY were the physicians in charge of the case. All of the authors contributed to the composition of this article and have read and approved the final manuscript.

References
1. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328-1337, 2004.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Volume 2. 2008.

3. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 13: 4992-5001, 2009.

4. Meijer E, Slaper-Cortenbach IC, Thijssen SF, Dekker AW, Verdonck LF. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique. Bone Marrow Transplant 29: 335-339, 2002.

5. van der Velden WJ, Mori T, Stevens WB, et al. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating preemptive rituximab. Blood Marrow Transplant 48: 1465-1471, 2013.

6. Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoietic SCT. Bone Marrow Transplant 49: 163-167, 2014.

7. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107: 1308-1314, 2006.

8. Camitta BM. What is the definition of cure for aplastic anemia? Acta Haematol 103: 16-18, 2000.

9. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anemia. Br J Haematol 147: 43-70, 2009.

10. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98: 972-978, 2001.

11. Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109: 3219-3224, 2007.

12. Viola GM, Zu Y, Baker KR, Aslam S. Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy. Med Oncol 28: 1604-1608, 2011.

13. Raghavachar A, Ganser A, Freund M, Heimpel H, Herrmann F, Schrezenmeier H. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther 2: 215-223, 1996.

14. Wondergem MJ, Stevens SJ, Janssen JJ, et al. Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression. Blood 111: 1739, author reply; 1739-1740, 2008.

15. Ohata K, Iwaki N, Kotani T, Kondo Y, Yamazaki H, Nakao S. An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia. Acta Haematol 127: 96-99, 2012.

16. Calistri E, Tiribelli M, Battista M, et al. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. Am J Hematol 81: 355-357, 2006.

17. Viola GM, Zu Y, Baker KR, Aslam S. Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy. Med Oncol 28: 1604-1608, 2011.

18. Sugimoto-Sekiguchi H, Tashiro H, Shirasaki R, et al. Colonic EBV-associated lymphoproliferative disorder in a patient treated with rabbit antithymocyte globulin for aplastic anemia. Case Rep GastroinTEST Med 2012: 395801, 2012.

19. Nakanishi R, Ishida M, Hodohara K, et al. Occurrence of Epstein-Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: a case report with review of the literature. International Journal of Clinical and Experimental Pathology 7: 1748-1756, 2014.

20. Takahashi Tohru, Maruyama Yumiko, Saitoh Mayuko, Itoh Hideko, Yoshimoto Mitsuru, Tsujiisaki Masayuki. Fatal Epstein-Barr virus reactivation in an acquired aplastic anemia patient treated with rabbit antithymocyte globulin and cyclosporine. A Case Reports in Hematology Volume, in press.

21. Hanaoka N, Murata S, Hosoi H, et al. B-cell-rich T-cell lymphoma associated with Epstein-Barr Virus virus-reactivation and T-cell suppression following antithymocyte globulin therapy in a patient with severe aplastic anemia. Hematol Rep 7: 5906, 2015.

22. Tsukamoto S, Nagao Y, Yamazaki A, et al. Successful allogeneic stem cell transplantation for severe aplastic anemia after treatment of lymphoproliferative disorder caused by rabbit antithymocyte globulin. Intern Med 54: 3197-3200, 2015.

23. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43: 757-770, 2009.

24. Bollard CM, Rooney CM, Hesplo HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9: 510-519, 2012.

25. Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematology 155: 377-385, 2011.

26. Styczynski J, Gil L, Tridello G, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 57: 794-802, 2013.

27. Xuan L, Jiang X, Sun J, et al. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoetic stem cell transplantation. Transplantation 96: 560-566, 2013.

28. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 121: 246-253, 2004.

29. Kempf C, Tinguely M, Rushing EJ. Posttransplant lymphoproliferative disorder of the central nervous system. Pathobiology 80: 310-318, 2013.

30. Kalita J, Maurya PK, Kumar B, Misra UK. Epstein Barr virus encephalitis: clinical diversity and radiological similarity. Neurology India 59: 605-607, 2011.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).